Results 11 to 20 of about 4,697 (156)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

HemaSphere, 2022
Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator’s choice of idelalisib plus rituximab (IdR) or bendamustine plus ...
Paolo Ghia, Andrzej Pluta, Małgorzata Wach, Daniel Lysak, Martin Šimkovič, Iryna Kriachok, Árpád Illés, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Ganna Usenko, Min Hui Wang, Ting Yu, Wojciech Jurczak   +17 more
doaj   +3 more sources

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia [PDF]

Haematologica, 2021
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients.
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps   +13 more
doaj   +2 more sources

Data Mining for Adverse Events Signals of Acalabrutinib Based on FAERS Database

Zhongliu Fangzhi Yanjiu, 2022
Objective To explore the potential adverse reactions of acalabrutinib by mining and analyzing the pharmacovigilance signal of acalabrutinib, to provide a reference for clinically safe and rational drug use.
LIANG Cuilyu, ZHANG Yin, CHEN Qiying
doaj   +2 more sources

The role of acalabrutinib in adults with chronic lymphocytic leukemia [PDF]

Therapeutic Advances in Hematology, 2021
The treatment landscape of chronic lymphocytic leukemia (CLL) has significantly changed in the past decade. This paradigm shift is due to the introduction of novel agents to the field. The two major classes of drugs that have contributed to this dramatic
Bita Fakhri, Charalambos Andreadis
doaj   +2 more sources

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. [PDF]

PLoS ONE, 2016
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib.
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth   +18 more
doaj   +2 more sources

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions [PDF]

Haematologica, 2019
While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two ...
Jennifer Series, Cédric Garcia, Marie Levade, Julien Viaud, Pierre Sié, Loïc Ysebaert, Bernard Payrastre   +6 more
doaj   +2 more sources

Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China

Therapeutic Advances in Hematology
Background: Acalabrutinib is a highly selective, latest generation Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Mengya Li, Xiaoyan Zhong, Chengbin Zhang, Hongli Luo, Li Luo, Yilan Huang, Longyang Jiang   +6 more
doaj   +2 more sources

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

Blood Advances, 2017
: The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib.
Alexander P. Bye, Amanda J. Unsworth, Michael J. Desborough, Catherine A.T. Hildyard, Niamh Appleby, David Bruce, Neline Kriek, Sophie H. Nock, Tanya Sage, Craig E. Hughes, Jonathan M. Gibbins   +10 more
doaj   +3 more sources

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [PDF]

, 2016
Background Irreversible inhibition of Bruton\u27s tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).
Jones, J. A., Harrington, B., Devereux, S., Furman, R. R., Chaves, J., Byrd, J. C., O\u27Brien, S., +20 additional authors, Wierda, W. G., Barrientos, J. C., Schuh, A.   +10 more
core   +4 more sources

The acalabrutinib-bound BTK kinase domain.

, 2023
a. Overall structure of the BTK KD/acalabrutinib complex. Key features of the kinase domain are labeled. Acalabrutinib is shown in yellow sticks and covalently attached to Cys481. Activation loop is colored red with Tyr551 shown in sticks.
Amy H. Andreotti (366314), David Y. Lin (16913868)   +1 more
core   +1 more source